TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03236792
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300, 400, or 500 mg of oral Cyclophosphamide on days 1, 8, and 15 of a 28-day cycle
Study: NCT00506181
Drug: probiotic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jarro-Dophilus probiotic mixture (4,400,000,000 bacteria in each capsule). One capsule X2/day.
Study: NCT00506181
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00296335
Drug: Mitomycin, doxifluridine and cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28- day 336), Cisplatin 60mg/m2 intravenously (day 28, day 56, day 84, day 112, day 140, and day 168)
Study: NCT00296335
Drug: Mitomycin and doxifluridine
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28-day 84)
Study: NCT00613496
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-tablet, 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8.
Study: NCT04068246
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet plus plus Methotrexate 7.5 mg weekly
Study: NCT03478696
Drug: Placebo to match FF/UMEC/VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to FF/UMEC/VI will be administered via ELLIPTA once daily in the morning.
Study: NCT03094156
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule of placebo \[to be taken orally, with 240 mL of potable water\]
Study: NCT03094156
Drug: BIA 6-512
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule of BIA 6-512 25mg or 1 capsule of BIA 6-512 50 mg or 1 capsule of BIA 6-512 75 mg or 1 capsule of BIA 6-512 100 mg \[to be taken orally, with 240 mL of potable water\]
Study: NCT03094156
Drug: Madopar® 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/benserazide immediate release tablets 200mg/50mg \[to be taken orally, with 240 mL of potable water\]
Study: NCT03094156
Drug: Comtan®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entacapone 200 mg tablets \[to be taken orally, with 240 mL of potable water\]
Study: NCT00997893
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol pill (1 mg)
Study: NCT00997893
Drug: Soy Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo pill (0mg Soy Phytoestrogen)
Study: NCT00997893
Drug: MPA Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo pill (0mg MPA)
Study: NCT02372461
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an non inferiority trial, the intervention is a placebo
Study: NCT00140972
Drug: MK0663; etoricoxib / Duration of Treatment:4 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00140972
Drug: Comparator: diclofenac sodium tablet 75 mg / Duration of Treatment:4 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00410124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02620592
Drug: ZYDPLA1 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: The oral dose of ZYDPLA1 tablet administered with 240 ± 10 mL of water at ambient temperature.
Study: NCT04452669
Drug: VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VentaProst delivered for up to 10 days via mechanical ventilation at a dose range that may be up or down titrated to a patient's clinical condition.
Study: NCT02620592
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: The oral dose of placebo tablet administered with 240 ± 10 mL of water at ambient temperature.
Study: NCT00003425
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00765492
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT04801836
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo tablet once per day
Study: NCT05641311
Drug: ALXN1840
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet for oral use.
Study: NCT01315886
Drug: SL fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SL fentanyl will be administered during 7- 15 BTcP episodes during a maximum period of 21 days, following a baseline period with standard BTcP treatment. The start dose of SL fentanyl is selected individually according to a standardized conversion ratio. The maximum start dose is limited to 400 μg. For a single BTcP episode no more than two (2) tablets or a maximum dose of 800 μg should be given.
Study: NCT02524288
Drug: ENG-E2 125 μg/300 μg vaginal ring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 13 cycles of ENG-E2 125 μg/300 μg administered intravaginally, each cycle consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
Study: NCT01311180
Drug: Sensoril®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Start with 250 mg po QAM for 7 days and then 250 mg po bid for 7 weeks
Study: NCT01311180
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Start with 250 mg po QAM for 7 days and then 250 mg po bid for 7 weeks
Study: NCT02558218
Drug: tobradex quid (Standard)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medication (tobradex quid for 20 days)
Study: NCT02107378
Drug: Standard of Care (Paclitaxel or topotecan or doxorubicin)
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel or topotecan or doxorubicin is Standard of Care First Line Chemotherapy
Study: NCT01026064
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zithromax (250 mg oral capsule).
Study: NCT01026064
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT01980095
Drug: RHB-105
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intended dose is RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:~* Rifabutin 150 mg~* Amoxicillin 3000 mg~* Omeprazole 120 mg~Subjects will take study drug every 8 hours with food for 14 consecutive days.
Study: NCT01980095
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take 4 placebo capsules every 8 hours with food for 14 days.
Study: NCT00488540
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppository
Study: NCT02009488
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo capsule (inactive medication) once daily.
Study: NCT01099891
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, Spray type, Twice a day
Study: NCT03671525
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two coconut oil capsules that mimic the size and color of the nimodipine capsules
Study: NCT03868033
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Use Zoledronic acid as a sequential therapy after denosumab treatment for more than 2 years
Study: NCT03744949
Drug: Remifentanil dose 0.5 ug/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil will be given (dosage of 0.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
Study: NCT03744949
Drug: Remifentanil dose 1 ug/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil will be given (dosage of 1 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
Study: NCT03744949
Drug: Remifentanil dose 1.5 ug/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil will be given (dosage of 1.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
Study: NCT03744949
Drug: Remifentanil dose 2 ug/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil will be given (dosage of 2 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
Study: NCT00873600
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02732314
Drug: Investigational OTC Cream
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00203229
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention type is 'drug' and this arm is a placebo pill created and supplied by the manufacturers of lamotrigine (Lamictal) to be exact replicas of the actual drug being studied. The placebo arm is titrated in the exact same manor as the active drug arm.
Study: NCT02279667
Drug: BIA 2-093
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral suspension 50 mg/mL
Study: NCT02279667
Drug: BIA 2-093
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tablet
Study: NCT02279667
Drug: BIA 2-093
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg tablet
Study: NCT01311336
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule orally once daily for 7 days beginning the day of administration of pegfilgrastim
Study: NCT04057807
Drug: LPS
Normalized name: ALPS LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS (0.4 ng/kg)
Study: NCT00537563
Drug: Telithromycin
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01482013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, once a day for 28 days.
Study: NCT01382342
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg daily
Study: NCT00889694
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 2 capsules per time, 3 times per day for 12 weeks.
Study: NCT03477396
Drug: Aromatase Inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor per treating investigator's discretion
Study: NCT01120106
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline continuous infusion
Study: NCT01193049
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets as a single oral dose on Day 1 of each study period
Study: NCT01951911
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01544062
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total of 6 doses of 1,000 mg IV acetaminophen at the following time points: (1) immediately after anesthesia induction, but prior to the incision, (2) at the end of surgery with (3) four additional doses administered postoperatively in the ICU every 6 hours for the first 24 hours.
Study: NCT01544062
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total of 6 doses of 100 mL of normal saline at the following time points: (1) immediately after anesthesia induction, but prior to the incision, (2) at the end of surgery with (3) four additional doses administered postoperatively in the ICU every 6 hours for the first 24 hours.
Study: NCT00092898
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01228513
Drug: ZK245186
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily topical application
Study: NCT01228513
Drug: Placebo (vehicle without active ingredient)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily topical application
Study: NCT00300040
Drug: 6% Hydroxyethylstarch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250ml for intravenous infusion
Study: NCT01830842
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: nonsmokers will be measured following placebo administration
Study: NCT00919763
Drug: CD2027 Ointment 3 mcg/g, twice daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Ointment
Study: NCT00919763
Drug: Vehicle Ointment, twice daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Ointment
Study: NCT02792036
Drug: Maxitrol®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxitrol® contains neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension and is for topical ophthalmic use only. It will be given for continued use for five days following the carboplatin injection to prevent infection.
Study: NCT00256243
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2 IV, bolus once every 14 days x 2-4 cycles
Study: NCT00256243
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2 IV once every 14 days x 2-4 cycles
Study: NCT03560310
Drug: ASA 75-160 mg daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assess whether ticagrelor 90 mg twice daily and ASA 75-100 mg daily versus ASA 75-160 mg daily improves outcome after isolated coronary artery bypass grafting in patients with acute coronary syndrome
Study: NCT00413179
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01677104
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00207532
Drug: folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04267250
Drug: Ethinyl estradiol (EE) and levonorgestrel (LN)
Normalized name: estradiol / ethinyl estradiol / levonorgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet containing 30 mcg EE and 150 mcg LN.
Study: NCT00547118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo tablet given 1 time per day for 112 days.
Study: NCT03103971
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02248480
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00165178
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction Phase: Intravenously on Days 0,1 Intensification Phase: Intravenously on Day 1 of each cycle
Study: NCT00165178
Drug: E. coli asparaginase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensification Phase: In the muscle weekly. Dose will vary
Study: NCT00165178
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction: Intravenously on Day 2 MLL Intensification: Intravenously on Days 1, 8 Intensification: (when doxorubicin completed) Intravenously or into the muscle weekly Continuation: Intravenously or into the muscle weekly
Study: NCT00165178
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction Phase: Intravenously or orally begins 36 hours after methotrexate MLL Intensification: Intravenously or orally begins 36 hours after methotrexate
Study: NCT00165178
Drug: Methotrexate/Hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction: Intrathecal on Days 14, 28 MLL Intensification: Intrathecal on Days 2,9
Study: NCT00005608
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02214290
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A 200 mg caffeine tablet was given to subject to examine the drugs effect on arterial function.
Study: NCT02214290
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 750 mg placebo capsule (maltodextrin) was given to subjects to examine the effect of the drug on arterial function.
Study: NCT03726268
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
Study: NCT03726268
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
Study: NCT00649610
Drug: valdecoxib
Normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: valdecoxib 40 mg QD for 7 days with a second dose of 40 mg the first day
Study: NCT00649610
Drug: diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: diclofenac 75 mg twice daily (BID) for 7 days
Study: NCT05283499
Drug: OPIOID
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic assignment
Study: NCT05283499
Drug: NON-OPIOID
Normalized name: Non-opioid analgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic assignment
Study: NCT02711826
Drug: Mycophenolic acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All enrolled participants will be on MPA (or MMF above) at the time of study entry at a minimum dose of 720mg per day.
Study: NCT02711826
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg acetaminophen, administered 30-60 minutes prior to infusion as pre-medication.
Study: NCT00241423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection, equivalent volume to 5 mcg exenatide twice a day for one week; then equivalent volume to 10 mcg exenatide twice a day for one week
Study: NCT02885350
Drug: Spinal analgesia for labour pain
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal dose of either fentanyl or sufentanil delivered by combined spinal-epidural technique
Study: NCT02885350
Drug: Epidural analgesia for labour pain
Normalized name: Arthricare for Women Pain Relieving Nighttime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural dose of either fentanyl or sufentanil delivered through an epidural catheter.
Study: NCT00324038
Drug: Codeine paracetamol
Normalized name: codeine and paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination tablet of codeine and paracetamol taken orally 3 or 4 times daily. Dosage form ranges from 8/500, 15/500 and 30/500
Study: NCT01514903
Drug: HIP0908
Approvals — FDA: no, EMA: no, PMDA: no
Description: SINGLE DOSE , CROSS OVER
Study: NCT00483405
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 850 mg/m2, orally, twice daily (dose rounded to accommodate 150 mg and 500 mg tablet sizes. Capecitabine given on days 1-14 of 21 day cycle.
Study: NCT02770430
Drug: conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Basiliximab 20mg dose for adults and 10mg for children, 1 time a week or every 3 days if worsens the stage of GVHD until reaching Very Good Partial Response (VGPR) or for a maximum of 4 doses, whichever comes first.~2. If after the item (1) will not obtained VGPR: Infliximab 5 to 10 mg/kg dose, 1 time a week, four weeks or even VGPR.
Study: NCT00741741
Drug: TMC278
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00410163
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (250 mg/m2) should be administered as an IV infusion daily, Days 2 through 4 of Course 1, and Days 1 through 3 of Courses 2 through 6, every 4 weeks for 6 courses.
Study: NCT00382616
Drug: Phosphatidylserine-Omega3
Normalized name: Phosphatidylserine
DrugBank: Phosphatidyl serine (DB00144)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00392223
Drug: Azithromycin microspheres
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin microspheres, powder for oral suspension, 2 g a week, in unique administration PO, repeated weekly for 8 weeks and minocycline-placebo capsules daily for 8 weeks plus minocycline placebo
Study: NCT00392223
Drug: minocycline-placebo capsules
Normalized name: minocycline Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: minocycline-placebo capsules daily for 8 weeks plus minocycline placebo
Study: NCT00392223
Drug: Azithromycin microspheres-placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline capsules, PO, 100 mg daily for 8 weeks and Azithromycin microspheres-placebo once a week for 8 weeks plus azithromycin placebo.
Study: NCT00392223
Drug: Minocycline capsules,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, PO, 100 mg daily for 8 weeks.
Study: NCT00622505
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid concentrate (4 mg/5 milliliters \[ml\]) was diluted in 100 mL sterile 0.9% calcium-free sodium chloride or 5% dextrose injection, administered IV, either 4 or 12 weeks for 96 weeks.
Study: NCT01396213
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: gelatin capsule
Study: NCT04359199
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin is a chemotherapy medication used to treat a number of cancers, including head and neck cancer
Study: NCT04411446
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 capsules of containing placebo orally given all at once. One dose.
Study: NCT04359199
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keytruda or Pembrolizumab is a highly selective humanized monoclonal IgG4 antibody directed against the PD-1 receptor on the cell surface.~Opdivo or Nivolumab is a targeted therapy. It is a human programmed death receptor-1 (PD-1) blocking antibody.~Imfinzi or Durvalumab is an anti-cancer (antineoplastic) drug. This medication is classified as an Anti-PD-L1 monoclonal antibody.
Study: NCT00912496
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile normal saline for injection (0.9% Sodium Chloride Injection, USP Preservative-Free).